40 Results for: "11-O-Methylpseurotin A&amp"

Supplier: MilliporeSigma

An antihyperglycemic agent that lowers blood glucose levels without stimulating insulin secretion, promoting weight gain or causing hypoglycemia. Reported to stimulate AMP-activated protein kinase (AMPK) leading to the reduction in acetyl-CoA carboxylase (ACC) activity and induction of fatty acid oxidation.

Supplier: Horizon Scientific

These General Purpose Refrigerator and Freezer Combination models are designed for laboratory use.

Supplier: MilliporeSigma

2-Amino-2-methyl-1-propanol hydrochloride for synthesis, CAS number 3207-12-3, Chemical formula (CH3)2C(NH2)CH2OH * HCl, Synonyms AMP hydrochloride 100g

Supplier: Anaspec Inc

This is a peptide substrate that is phosphorylated by Serine/Threonine kinase 11 (STK11), also known as LKB1. LKBtide is derived from sucrose non-fermenting 1 (SNF1) protein kinase, which is normally activated by the LKB1/AMP-activated protein kinase (AMPK) signaling pathway.
Sequence:LSNLYHQGKFLQTFCGSPLYRRR
MW:2785.2 Da
% peak area by HPLC:95
Storage condition:-20° C

Supplier: SPEX CERTIPREP LLC

The Pipette Washer and Dryer was designed by SPEX CertiPrep® chemists to take the hassle out of washing Class A volumetric pipettes.

Supplier: Thermo Fisher Scientific

This wireless monitoring solution for laboratory equipment safeguards the integrity of precious samples by continuously monitoring critical parameters and securely logging data to provide unprecedented peace-of-mind. Featuring audit trail traceability, this solution assists with conformance to 21 CFR Part 11, and other strenuous regulatory requirements for labs operating in regulated industries. System features software, modules, repeaters, receivers, and a 915 Mhz frequency (North America).

Supplier: Genetex

One of the many phosphodiesterases that compartmentalize and hydrolyze cAMP and cGMP into AMP and GMP is Phosphodiesterase type 11. The human PDE11A contains an open reading frame encoding a 490 amino acid protein (55-56 kDa). The PDE11A has an N-terminus GAF domain homologous to other signaling molecule as found in PDE2, PDE5, PDE6, PDE10, which potentially represents an allosteric cGMP and other small signaling molecules. PDE11A hydrolyzes both cGMP and cAMP; it is sensitive to non-selective PDE inhibitor IBMX as well as zaprinast and dipyrimadole inhibitors that are generally selective for cGMP-specific enzymes. PDE11A expression is diverse and is found in high levels in skeletal muscle, prostate, kidney, liver, pituitary and testis.

Supplier: Genetex

One of the many phosphodiesterases that compartmentalize and hydrolyze cAMP and cGMP into AMP and GMP is Phosphodiesterase type 11. The human PDE11A contains an open reading frame encoding a 490 amino acid protein (55-56 kDa). The PDE11A has an N-terminus GAF domain homologous to other signaling molecule as found in PDE2, PDE5, PDE6, PDE10, which potentially represents an allosteric cGMP and other small signaling molecules. PDE11A hydrolyzes both cGMP and cAMP; it is sensitive to non-selective PDE inhibitor IBMX as well as zaprinast and dipyrimadole inhibitors that are generally selective for cGMP-specific enzymes. PDE11A expression is diverse and is found in high levels in skeletal muscle, prostate, kidney, liver, pituitary and testis.

Supplier: Bellco Glass

Standard orbital shaker ideal for hybridization and gel agitation.

Supplier: Alere

Rapid Drug Screen for the simultaneous, qualitative detection of single or multiple drug metabolites in human urine

Supplier: Sakura Finetek

3D Precision Chuck for rapid tissue alignment. Software enables an accumulated section count of number of sections made and the total thickness cut in microns.

Supplier: Enzo Life Sciences

Inhibitor of a variety of serine/threonine and tyrosine kinases, like protein kinase C (PKC), cyclic AMP-dependent protein kinase (PKA), S6 kinase, Akt (protein kinase B; PKB), epidermal growth factor receptor (EGFR) tyrosine kinase activity and others including KDR, VEGFR, PDGFR, c-kit and other receptor tyrosine kinases. Potently inhibits FLT-3 kinase including mutant forms found in acute myeloid leukemia in vitro and in vivo. Apoptosis inducer. Showed broad antiproliferative activity against various tumor cell lines. Selectively inhibits T lymphocyte production of TNF-α. Upregulates endothelial nitric oxide synthase (eNOS; NOS III). Abrogates tumor angiogenesis in vivo.

Supplier: Bioss

Vasopressin (AVP), the antidiuretic hormone, is a cyclic nonpeptide that is involved in the regulation of body fluid osmolality (1-3). AVP mediates its effects through a family of G-protein coupled receptors, the vasopressin receptors type V1a, V2 and V3 (also designated V1b) (1,2). The AVP receptor V1a is responsible for several functions, including blood vessel constriction, liver glycogenolysis and platelet adhesion (3). It is detected as a full length protein and a shorter protein, which results from proteolytic cleavage of its amino terminus (4). The V1a receptor is coupled to Gq/11 protein, which increases the intracellular calcium concentration (3). The human AVP receptor V2 gene maps to chromosome Xq28 and is expressed in lung and kidney (5,6). Mutations in the V2 receptor result in nephrogenic diabetes insipidus (NDI), a rare X-linked disorder characterized by the inability of the kidney to concentrate urine in response to AVP (5,7). The AVP Receptor V2 activates the Gs protein and the cyclic AMP second messenger system (7). The AVP receptor V3 is preferentially expressed in the pituitary and stimulates the release of adrenocorticotropic hormone (ACTH) in response to AVP by mobilizing intracellular calcium stores (8). AVP receptor antagonists may have potential therapeutic effects in hypertension, congestive heart failure, nephrotic syndrome and ACTH-secreting tumors (2).

Supplier: Bioss

Vasopressin (AVP), the antidiuretic hormone, is a cyclic nonpeptide that is involved in the regulation of body fluid osmolality (1-3). AVP mediates its effects through a family of G-protein coupled receptors, the vasopressin receptors type V1a, V2 and V3 (also designated V1b) (1,2). The AVP receptor V1a is responsible for several functions, including blood vessel constriction, liver glycogenolysis and platelet adhesion (3). It is detected as a full length protein and a shorter protein, which results from proteolytic cleavage of its amino terminus (4). The V1a receptor is coupled to Gq/11 protein, which increases the intracellular calcium concentration (3). The human AVP receptor V2 gene maps to chromosome Xq28 and is expressed in lung and kidney (5,6). Mutations in the V2 receptor result in nephrogenic diabetes insipidus (NDI), a rare X-linked disorder characterized by the inability of the kidney to concentrate urine in response to AVP (5,7). The AVP Receptor V2 activates the Gs protein and the cyclic AMP second messenger system (7). The AVP receptor V3 is preferentially expressed in the pituitary and stimulates the release of adrenocorticotropic hormone (ACTH) in response to AVP by mobilizing intracellular calcium stores (8). AVP receptor antagonists may have potential therapeutic effects in hypertension, congestive heart failure, nephrotic syndrome and ACTH-secreting tumors (2).

Supplier: Bioss

Vasopressin (AVP), the antidiuretic hormone, is a cyclic nonpeptide that is involved in the regulation of body fluid osmolality (1-3). AVP mediates its effects through a family of G-protein coupled receptors, the vasopressin receptors type V1a, V2 and V3 (also designated V1b) (1,2). The AVP receptor V1a is responsible for several functions, including blood vessel constriction, liver glycogenolysis and platelet adhesion (3). It is detected as a full length protein and a shorter protein, which results from proteolytic cleavage of its amino terminus (4). The V1a receptor is coupled to Gq/11 protein, which increases the intracellular calcium concentration (3). The human AVP receptor V2 gene maps to chromosome Xq28 and is expressed in lung and kidney (5,6). Mutations in the V2 receptor result in nephrogenic diabetes insipidus (NDI), a rare X-linked disorder characterized by the inability of the kidney to concentrate urine in response to AVP (5,7). The AVP Receptor V2 activates the Gs protein and the cyclic AMP second messenger system (7). The AVP receptor V3 is preferentially expressed in the pituitary and stimulates the release of adrenocorticotropic hormone (ACTH) in response to AVP by mobilizing intracellular calcium stores (8). AVP receptor antagonists may have potential therapeutic effects in hypertension, congestive heart failure, nephrotic syndrome and ACTH-secreting tumors (2).

Supplier: Bioss

Vasopressin (AVP), the antidiuretic hormone, is a cyclic nonpeptide that is involved in the regulation of body fluid osmolality (1-3). AVP mediates its effects through a family of G-protein coupled receptors, the vasopressin receptors type V1a, V2 and V3 (also designated V1b) (1,2). The AVP receptor V1a is responsible for several functions, including blood vessel constriction, liver glycogenolysis and platelet adhesion (3). It is detected as a full length protein and a shorter protein, which results from proteolytic cleavage of its amino terminus (4). The V1a receptor is coupled to Gq/11 protein, which increases the intracellular calcium concentration (3). The human AVP receptor V2 gene maps to chromosome Xq28 and is expressed in lung and kidney (5,6). Mutations in the V2 receptor result in nephrogenic diabetes insipidus (NDI), a rare X-linked disorder characterized by the inability of the kidney to concentrate urine in response to AVP (5,7). The AVP Receptor V2 activates the Gs protein and the cyclic AMP second messenger system (7). The AVP receptor V3 is preferentially expressed in the pituitary and stimulates the release of adrenocorticotropic hormone (ACTH) in response to AVP by mobilizing intracellular calcium stores (8). AVP receptor antagonists may have potential therapeutic effects in hypertension, congestive heart failure, nephrotic syndrome and ACTH-secreting tumors (2).

Supplier: Bioss

Vasopressin (AVP), the antidiuretic hormone, is a cyclic nonpeptide that is involved in the regulation of body fluid osmolality (1-3). AVP mediates its effects through a family of G-protein coupled receptors, the vasopressin receptors type V1a, V2 and V3 (also designated V1b) (1,2). The AVP receptor V1a is responsible for several functions, including blood vessel constriction, liver glycogenolysis and platelet adhesion (3). It is detected as a full length protein and a shorter protein, which results from proteolytic cleavage of its amino terminus (4). The V1a receptor is coupled to Gq/11 protein, which increases the intracellular calcium concentration (3). The human AVP receptor V2 gene maps to chromosome Xq28 and is expressed in lung and kidney (5,6). Mutations in the V2 receptor result in nephrogenic diabetes insipidus (NDI), a rare X-linked disorder characterized by the inability of the kidney to concentrate urine in response to AVP (5,7). The AVP Receptor V2 activates the Gs protein and the cyclic AMP second messenger system (7). The AVP receptor V3 is preferentially expressed in the pituitary and stimulates the release of adrenocorticotropic hormone (ACTH) in response to AVP by mobilizing intracellular calcium stores (8). AVP receptor antagonists may have potential therapeutic effects in hypertension, congestive heart failure, nephrotic syndrome and ACTH-secreting tumors (2).

Supplier: Bioss

Vasopressin (AVP), the antidiuretic hormone, is a cyclic nonpeptide that is involved in the regulation of body fluid osmolality (1-3). AVP mediates its effects through a family of G-protein coupled receptors, the vasopressin receptors type V1a, V2 and V3 (also designated V1b) (1,2). The AVP receptor V1a is responsible for several functions, including blood vessel constriction, liver glycogenolysis and platelet adhesion (3). It is detected as a full length protein and a shorter protein, which results from proteolytic cleavage of its amino terminus (4). The V1a receptor is coupled to Gq/11 protein, which increases the intracellular calcium concentration (3). The human AVP receptor V2 gene maps to chromosome Xq28 and is expressed in lung and kidney (5,6). Mutations in the V2 receptor result in nephrogenic diabetes insipidus (NDI), a rare X-linked disorder characterized by the inability of the kidney to concentrate urine in response to AVP (5,7). The AVP Receptor V2 activates the Gs protein and the cyclic AMP second messenger system (7). The AVP receptor V3 is preferentially expressed in the pituitary and stimulates the release of adrenocorticotropic hormone (ACTH) in response to AVP by mobilizing intracellular calcium stores (8). AVP receptor antagonists may have potential therapeutic effects in hypertension, congestive heart failure, nephrotic syndrome and ACTH-secreting tumors (2).

Supplier: MP Biomedicals

Forskolin is the major diterpene isolated from the Indian plant Coleus forskohlii. At low doses, forskolin is a positive inotropic agent in dogs, cats, spontaneously hypertensive and normal rats and in an isolated guinea pig heart (Langendorf) preparation. At higher doses, forskolin is a hypotensive and vasodilatory agent because of its function as a smooth muscle relaxant. No major side effects are observed at effective doses.

Supplier: MP Biomedicals

1,1-Dimethylbiguanide hydrochloride is suitable biguanide agent used in a study to investigate its role in enhancing the secretions of plasma active glucagon-like peptide-1 (GLP-1) levels.

Supplier: Germaine Laboratories

Rapid qualitative tests for the detection of drugs of abuse in urine.

Supplier: Prosci

Polyclonal, Host: Goat; Target Species: Human; Immunogen: PRKAA2 antibody was raised against an 11 amino acid synthetic peptide near the internal region of PRKAA2; Applications: ELISA,Western blotting

Supplier: GLOBEPHARMA

Unit-dose and bulk powder, liquid, and semi-solid samplers available in various lengths and configurations.

Supplier: GLOBEPHARMA

Unit-dose and bulk powder, liquid and semi-solid samplers available in various lengths and configurations.

Supplier: GLOBEPHARMA

Unit-dose and bulk powder, liquid, and semi-solid samplers available in various lengths and configurations.

Supplier: Prosci

LKB1 Antibody: The LKB1 serine/threonine protein kinase was initially identified as a tumor suppressor gene mutated in human Peutz-Jeghers syndrome (PJS), a condition resulting in the growth of numerous intestinal polyps classed as hamartomas. LKB1 exists as a heterotrimeric complex with two other proteins, Ste20-related adaptor protein (STRAD) and MO25. Together, this complex can phsophorylate and activate the AMP-activate protein kinase (AMPK). Following AMPK activation by LKB1, AMPK then phosphorylates TSC1 and TSC2, key components of the metabolism-regulating TOR signaling pathway, which antagonizes the activation for the TOR pathway. LKB1 has also been shown to play a fundamental role in controlling the spatial orientation of structures required to maintain an ordered, polarized epithelium.

Supplier: Thermo Fisher Scientific

Dependable –86 °C storage, powered by H-drive for operational savings and sustainability.

Supplier: ANTIBODIES.COM LLC

Human Gastrokine 1 ELISA kit is a 90 minutes sandwich Enzyme-Linked Immunosorbent Assay (sELISA) designed for the in vitro quantitative determination of human Gastrokine 1 in serum, plasma, and other biological fluids.

Supplier: ANTIBODIES.COM LLC

Mouse Gastrokine 1 ELISA kit is a 90 minutes sandwich Enzyme-Linked Immunosorbent Assay (sELISA) designed for the in vitro quantitative determination of mouse Gastrokine 1 in serum, plasma, and other biological fluids.

Supplier: ANTIBODIES.COM LLC

Human Gastrokine 1 ELISA kit is a sandwich Enzyme-Linked Immunosorbent Assay (sELISA) designed for the in vitro quantitative determination of human Gastrokine 1 in serum, plasma, tissue homogenates, and other biological fluids.